Healthy Males

3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Genomics
GenomicsUK - Oxford
1 program
1
FiribastatPhase 1Small Molecule1 trial
Active Trials
NCT03714685Completed12Est. Jun 2019
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
NaloxonePhase 11 trial
Active Trials
NCT01367561CompletedEst. May 2003
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1203Phase 11 trial
Active Trials
NCT04234594UnknownEst. Sep 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalQL1203
GenomicsFiribastat
Bausch HealthNaloxone

Clinical Trials (3)

Total enrollment: 12 patients across 3 trials

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

Start: Oct 2019Est. completion: Sep 2020
Phase 1Unknown

Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations

Start: Feb 2019Est. completion: Jun 201912 patients
Phase 1Completed

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Start: Oct 2002Est. completion: May 2003
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space